Interindividual Variability in Cytochrome P450-Mediated Drug Metabolism

Timothy S. Tracy, Amarjit S. Chaudhry, Bhagwat Prasad, Kenneth E. Thummel, Erin G. Schuetz, Xiao-bo Zhong, Yun-Chen Tien, Hyunyoung Jeong, Xian Pan, Laura M. Shireman, Jessica Tay-Sontheimer, Yvonne S. Lin

Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, KY 40536 (T.T.)

Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN 38105 (A.S.C. and E.G.S.)

Department of Pharmaceutical Sciences, School of Pharmacy, University of Connecticut, Storrs, CT 06269 (X.B.Z. and Y.C.T)

Department of Pharmaceutics, School of Pharmacy, University of Washington, Seattle, WA 98195 (B.P., K.E.T., L.M.S., J.T.-S., and Y.S.L.)

Departments of Pharmacy Practice and Biopharmaceutical Sciences, College of Pharmacy, University of Illinois at Chicago, Chicago, IL 60612 (H.J. and X.P.)

Running Title: Interindividual variability in P450s

Correspondence:

Hyunyoung Jeong, PharmD, PhD

Departments of Pharmacy Practice and Biopharmaceutical Sciences

College of Pharmacy, University of Illinois at Chicago

900 S. Ashland Ave, Chicago, IL 60612

Phone: 312-996-7820

Fax: 312-996-0379

E-mail: yjeong@uic.edu

 # text pages: 30

 # tables: 2

 # figures: 0

 # references: 93

 # words in the Abstract: 216

 # words in the Introduction: 714

 # words in the Discussion: n/a

Abbreviations

AKR1D1, aldo-keto reductase 1D1; CAR, constitutive androstane receptor; FXR, farnesoid X receptor; HNF, hepatocyte nuclear factor; OAT, organic anion transporter; PXR, pregnane X receptor; SHP, small heterodimer partner; SNP, single nucleotide polymorphism

ABSTRACT

The cytochrome P450 (P450) enzymes are the predominant enzyme system involved in human drug metabolism. Alterations in the expression and/or activity of these enzymes result in changes in pharmacokinetics (and consequently the pharmacodynamics) of drugs that are metabolized by this set of enzymes. Apart from changes in activity due to drug-drug interactions (by P450 induction or inhibition), the P450 enzymes can exhibit substantial interindividual variation in basal expression and/or activity, leading to differences in the rates of drug elimination and response. This interindividual variation can result from a myriad of factors including genetic variation in the promoter or coding regions, variation in transcriptional regulators, alterations in micro-RNA that impact P450 expression, and ontogenic changes due to exposure to xenobiotics during the developmental and early post-natal periods. Other than administering a probe drug or cocktail of drugs to obtain the phenotype or conducting a genetic analysis to determine genotype, methods to determine inter-individual variation are limited. Phenotyping via a probe drug requires exposure to a xenobiotic, and genotyping is not always well correlated with phenotype, making both methodologies less than ideal. This manuscript describes recent work evaluating the impact of some of these factors on interindividual variation in human P450-mediated metabolism and the potential utility of endogenous probe compounds to assess rates of drug metabolism among individuals.

Introduction

Xenobiotics, including therapeutic agents, typically undergo chemical modification in the body to aid their elimination. The cytochrome P450 monooxygenase enzymes (P450s) are the predominant enzyme system involved in human drug metabolism, accounting for about 75% of the total reactions for drug metabolism in human liver, intestine, and kidney (Guengerich, 2008). The rate at which drugs and xenobiotics are metabolized by the P450s affects the pharmacokinetics of the compound and consequently, may also impact the pharmacodynamic response (Sim et al., 2013). Drug interactions involving either induction or inhibition of P450 enzymes can alter rates of P450-mediated metabolism. However, significant interindividual variation in basal rates of P450-mediated drug metabolism have been observed, including up to 30- to 40-fold variation for CYP3A enzymes (Westlind et al., 1999; Lamba et al., 2002; Hart et al., 2008), 100-fold variation for CYP2D6 (Hart et al., 2008), 50- to 60-fold variation for CYP2B6 (Saitoh et al., 2007), and 40- to 50-fold variation for CYP2C9 (Hart et al., 2008).

Pharmacogenetic variation associated with changes in the amino acid sequence of the coding region accounts for some of the basal interindividual variation in P450-mediated metabolism in humans. Clinically relevant examples of this pharmacogenetic variation have been observed with CYP2C9 (for warfarin) (Cooper et al., 2008; Takeuchi et al., 2009), CYP2C19 (for clopidogrel and omeprazole) (Hou et al., 2014), CYP2D6 (for tamoxifen and codeine) (Madadi et al., 2013; Gryn et al., 2014), and CYP3A5 (for tacrolimus) (Rojas et al., 2014). In some instances, the resulting protein is still functional but exhibits reduced activity (e.g., CYP2C9 (Steward et al., 1997)), whereas in other cases, the resulting variant protein may be completely devoid of activity or is not expressed (e.g., CYP2D6 (Dahl et al., 1992), CYP2C19 (de Morais et al., 1994), and CYP3A5 (Kuehl et al., 2001)). Depending on whether metabolism produces an active (e.g., clopidogrel) or inactive metabolite (e.g., warfarin), the consequences of these polymorphisms can result in significant alternations in therapeutic effect.

Beyond differences in rates of P450 metabolism due to coding region changes, investigators have explored whether other factors contribute to interindividual variation in basal P450 activity. These factors include genetic variation in promoter regions, altered expression of micro-RNA that impact P450

4

expression, genetic variation in transcriptional regulators, and the influence of modulating agents early in development, among others. Genetic variation in the promoter region of P450 enzymes can result in altered levels of expression which in turn lead to alterations in rates of drug metabolism (Lamba et al., 2008). Likewise, variability in expression of micro-RNA have been demonstrated to alter expression of P450s (Lamba et al., 2014). Though less well studied, genetic variations in the non-coding region play an important role in the interindividual variation of human drug metabolism. Finally, the ontogeny of drug-metabolizing enzymes has been established by several investigators (Lacroix et al., 1997; Stevens, 2006; Hines, 2007). These studies have demonstrated that P450s mature at different rates throughout development, with some reaching adult activity shortly after birth, some taking several years before reaching full activity, and some even peaking and then diminishing after birth (Hines, 2007). However, little is known about the influence of environment or exposure to drugs or other xenobiotics on their long-term expression and activity.

Regardless of the cause of interindividual variation, it is desirable to determine an individual's phenotype in the most rapid and least invasive manner. Typically, this has been accomplished by administering a "probe" compound and measuring the pharmacokinetics of the probe compound. Probe compounds have been studied for most P450s, and for some P450s, multiple probe compounds have been identified. To assess the phenotype of several drug-metabolizing enzymes simultaneously, a "cocktail" of probe compounds can be used. However, ideally one would not have to administer an exogenous compound (or compounds), but be able to evaluate an individual's phenotype through measurement of endogenous compounds and their pharmacokinetics. Cortisol and its metabolite, 6β-hydroxycortisol, are examples of endogenous compounds that have been used for CYP3A phenotyping (Galteau and Shamsa, 2003).

This symposium describes the work spanning genetic variation, regulation, development, and activity of P450s of four laboratories. The roles of transcriptional regulators, their genetic variation, xenobiotic exposure during the early developmental period in interindividual variation in human drug

metabolism, as well as metabolomic approaches to predicting individual rates of human drug metabolism are described.

Genetic Predictors of P450 Expression and Activity (E.G.S., B.P., K.E.T., and A.S.C.)

Genetic polymorphisms have been identified for most human P450s. Many of these variant alleles contribute to interindividual differences in gene expression and/or enzyme activity, and consequently, underlie disease susceptibility and pharmacokinetic variability. Nevertheless, a large percentage of interindividual variation in P450 activities remains unexplained by common *cis*-variation. This talk reviewed the unique value of using a human liver resource as a basic biology discovery platform to identify *cis*- and *trans*-genetic variants and their P450 phenotypic consequences.

Somewhat surprisingly, we found a significant degree of co-regulation in mRNA expression between some of the major human hepatic drug-metabolizing enzymes (Chaudhry et al., 2013). For example, the mRNA expression of *CYP2C19, CYP2B6,* and *CYP3A4*, were highly correlated despite the fact that these genes are on different chromosomes. Indeed, there are polymorphisms in shared hepatic transcriptional regulators of these P450s (e.g., hepatocyte nuclear factor (HNF) 4β, FOXA2, FOXA3 and pregnane X receptor (PXR)). However, only about 10% of the variation in target P450 expression is explained by these *trans*-factor polymorphisms (Lamba et al., 2010).

In a collaborative study, we constructed an unbiased weighted co-expression network and a Bayesian regulatory network by using whole genome mRNA expression in >400 human livers (Yang et al., 2010). A novel candidate regulatory gene, *AKR1D1* (aldo-keto reductase 1D1), was identified as one master regulator driving co-expression of the P450 network. AKR1D1 was a reasonable candidate regulating P450 expression because of its central role in regulating bile acid concentrations in liver. Bile acids can activate nuclear receptors such as PXR, farnesoid X receptor (FXR), and constitutive androstane receptor (CAR). We used adenovirus to overexpress AKR1D1 and siRNA to knockdown AKR1D1 expression in primary human hepatocytes to evaluate AKR1D1's role in regulating P450 expression. *CYP3A4, 2C8, 2C9, 2C19*, and *2B6* mRNA expression was decreased by knockdown of AKR1D1, while

AKR1D1 overexpression increased epression of these P450s. The *AKR1D1* cDNA was resequenced in livers from ~100 donors. A 3′-UTR (rs1872930) single nucleotide polymorphism (SNP) was identified that was associated with higher mRNA expression of *AKR1D1*. The *AKR1D1* 3′-UTRs from the wild-type and variant alleles were engineered into luciferase reporters and transfected into HepG2 cells. Consistent with its mRNA expression, the variant 3′-UTR reporter had luciferase activity higher than the wild-type construct. This result suggests the 3′-UTR SNP can increase either *AKR1D1* mRNA translational efficiency or *AKR1D1* mRNA stability. In addition, the 3′-UTR SNP in *AKR1D1* was significantly associated with mRNA expression and P450 activity of CYP2B6, CYP2C19, CYP2C8 and CYP3A4. In total, this study revealed that genetic variation in a master regulator (AKR1D1) of the P450 network can predict activity of numerous P450s in the network. Hence, identifying hub regulatory genes in P450 expression networks is an alternative way to identify genes whose genetic variation may alter P450 activity. Interestingly, this study demonstrates that genetic variation in genes, like *AKR1D1*, is an important contributor to variation in P450 activity, by influencing the level of ligands that activate nuclear receptors responsible for the transcriptional regulation of P450s (e.g., bile acids) (Chaudhry et al., 2013).

Another unique value of the human liver resource is that it offers a rich and robust resource of phenotypic variation that can be used to identify associated genotypic variation affecting mRNA processing (e.g., splicing). Because splicing is highly tissue-specific, and the liver shows an unusually high level of alternative pre-mRNA splicing per gene compared to other tissues, the functional consequence of SNPs in hepatic genes have the greatest probability of generating unique liver-specific phenotypes that can only be detected in hepatic samples. Indeed, a single agarose gel analysis of *CYP* PCR products is able to quickly identify unique alternative mRNAs that are "polymorphically" expressed – that is, their expression is not proportional to the amount of canonical mRNA, and is uniquely/polymorphically expressed only in some human livers. This approach was successfully used to identify the causative SNPs that lead to alternative splicing and polymorphic expression of *CYP3A5*3*, *CYP3A5*6* (Kuehl et al., 2001) and *CYP2B6*6* (Lamba et al., 2003).

In the course of PCR amplification of *CYP2C19* to sequence and identify additional variants, we found that amplification from exons 2 to 4 revealed a novel alternative *CYP2C19* mRNA in a substantial number of human livers. This *CYP2C19* alternative mRNA was perfectly correlated with an intron 2 SNP, rs12769205 (Chaudhry et al., 2015). A survey of multiple genomic databases indicated rs12769205 and rs4244285 are in likage disequelibirium with *CYP2C19*2* (Figure 1A). However, in Blacks (African ancestry), rs12769205 can also exist alone in *CYP2C19*35*. Notably, rs4244285, the SNP that defines *CYP2C19*2*, is located in exon 5 and leads to alternative splicing of the first 40 base pairs of this exon, ultimately changing the mRNA reading frame and leading to a premature termination codon. For two decades rs4244285 was thought to be the exclusive SNP leading to loss of *CYP2C19*2* function. This new SNP, rs12769205 in an intron 2 branch point adenine, leads to alternative splicing of this allele due to inclusion of all of intron 2, alteration of the reading frame, and a premature termination codon in *CYP2C19*2*. Minigene experiments showed that rs12769205 alone leads to inclusion of intron 2. To determine the independent contribution of each SNP to CYP2C19 protein expression in livers with *CYP2C19*2*, we used a quantitative proteomics with tandem mass spectrometry approach. The amount of CYP2C9 protein was quantified in wild-type and homozygous *CYP2C19*2* livers (with both rs12769205 and rs4244285). In persons homozygous for both SNPs, some residual CYP2C19 protein was detectable with the exon 2 probe (which is 5′ of both SNPs), however no CYP2C19 protein was detectable with the exon 4 probe (which is 5′ of rs4244285, but downstream of the intron 2 SNP). This result shows that rs12769205 in intron 2 can lead to the loss of CYP2C19 protein because of its preeminence in *CYP2C19* mRNA splicing.

We determined whether *CYP2C19*35* and *CYP2C19*2* are under natural selection in populations with African ancestry, and which allele arose first. Phylogenetic tree analysis of *CYP2C19* haplotypes across African populations showed that rs12769205 was the original polymorphism arising first on *CYP2C19*35* and that *CYP2C19*2* was created later after the addition of rs4244285 (Figure 1A). The final evidence that rs12769205 is functionally important came from screening *CYP2C19*2* and

8

CYP2C19*35 for natural selection in African populations, such as the Yorubans. In all African populations examined, there was significant evidence that both haplotypes carrying rs12769205 had undergone natural selection. Indeed, the degree of natural selection on both alleles carrying rs12769205 (*CYP2C19*35* and *CYP2C19*2*) was similar in magnitude to the evolutionary force seen for genes, such as glucose-6-phosphate dehydrogenase and TNF receptor superfamily member 5, that are under natural selection from infectious diseases such as malaria (Figure 1B). This supports the data that rs12769205 has a significant functional effect exclusive of rs4244285. Hence, rs12769205 is the original ancestral polymorphism leading to abnormal splicing and intron 2 retention in both *CYP2C19*35* and *CYP2C19*2*.

Impact of Drug Treatment at Early Life on Interindividual Variations of P450-mediated Drug Metabolism in Adult Liver (X.B.Z. and Y.C.T.)

Significant variation in P450 activities has been found during development, from prenatal through birth, infant, and child, to adolescent and adult (Hines, 2007). For example, CYP3A4 and CYP3A7 are differentially expressed at different developmental ages (Lacroix et al., 1997; Stevens, 2006). CYP3A7 is the predominant CYP3A enzyme expressed in fetal and early postnatal liver tissues and then generally decreases over a few years to an undetectable level for the rest of life. Conversely, CYP3A4 is not detectable before birth, but gradually increases postnatally and is the dominant CYP enzyme in adult liver and intestine. The differences in catalytic activities and gene expression of CYP3A4 and CYP3A7 can lead to differences in drug metabolism and responses between pediatric and adult patients. An ontogenic pattern with increased gene expression has also been found in CYP2B6 (Croom et al., 2009), CYP2C9, and CYP2C19 (Koukouritaki et al., 2004). Using the mouse as a model, we have demonstrated that ontogenic expression of P450 genes in liver is a programmed biological process (Peng et al., 2012). The similarity of ontogenic gene expression patterns has been observed between human CYP3A4 and mouse Cyp3a11, human CYP2B6 and mouse Cyp2b10, and human CYP2C9 and mouse Cyp2c29. For some mouse P450s, such as Cyp3a11 and Cyp3a16, ontogenic gene expression patterns are associated with

epigenetic signatures, such as histone methylation, during liver maturation at postnatal development (Li et al., 2009).

Induction of P450 expression by drugs or other xenobiotic compounds also has clinical implications (Lin and Lu, 1998). Induction of P450 expression by drugs may result in an increased rate of P450-mediated drug metabolism, which may correspond to a decrease in therapeutic effect of the victim drug. It is known that some drugs can serve as ligands to activate transcription factors, such as nuclear receptors, and thus induce the expression of P450 genes (Handschin and Meyer, 2003). For example, rifampicin, hyperforin, or phenobarbital induces CYP3A4, CYP2C9, or CYP2B6 through the direct or indirect activation of PXR or CAR (Gervot et al., 1999; Goodwin et al., 1999; Sueyoshi et al., 1999; Goodwin et al., 2001; Chen et al., 2004). Induction of P450 enzymes by drugs has been identified as a factor that can contribute to interindividual variability of drug response (Lin and Lu, 2001).

Treatment with drugs during early life may have a long-term effect on persistent induction of P450 gene expression throughout the rest of life. Neonatal exposure to phenobarbital has shown an over-induction of P450 expression in adult liver through an imprinting mechanism in a rat model (Agrawal and Shapiro, 2003), which could result in reduced life expectancy and enhanced susceptibility to tumorigenesis (Agrawal and Shapiro, 2005). Neonatal activation of the nuclear receptor CAR by TCPOBOP (a CAR ligand) also resulted in permanent changes of P450 expression in adult mouse livers through a mechanism that altered epigenetic memory (Chen et al., 2012), including a permanent increase of histone 3 lysine 4 mono-, di-, and trimethylation and decrease of histone 3 lysine 9 trimethylation within the Cyp2b10 locus. Transcriptional coactivator activating signal cointegrator-2 and histone demethylase JMJD2d are involved in the CAR-dependent alteration of epigenetic memory. These studies imply that drug treatment of neonates or infants may have a lifelong effect on the rate of P450-mediated drug metabolism.

In this talk, we reported that the dose of drug and age of treatment in early life are two key factors for the persistent induction of gene expression and consequent increases of enzyme activities of several

10

P450 genes in Cyp2b, Cyp2c, and Cyp3a subfamilies in adult mouse liver (Tien et al., 2015). When mice mature under normal conditions (no drug treatment in early life), their P450 expression follows the typical ontogenic pattern with increased expression with age (Peng et al., 2012). Exposure to a low dose of phenobarbital (<100 mg/kg) early in life (day 5) resulted in an acute induction of Cyp2b, Cyp2c, and Cyp3a, but P450 levels returned to baseline levels after a few days, and were similar to livers from control mice at day 60. Exposure to high dose phenobarbital (>200 mg/kg) in early life (day 5) resulted in a persistent induction of gene expression in mouse liver throughout adulthood (Figure 2A). However, exposure to high dose phenobarbital (>200 mg/kg) in later life (day 20) did not result in such persistent induction (Figure 2B). In summary, we found that phenobarbital treatment in early life with a low dose (<100 mg/kg) did not change expression and enzyme activities of Cyp2b, Cyp2c, and Cyp3a in adult mouse liver, whereas phenobarbital treatment at a high dose (>200 mg/kg) significantly increased expression and enzyme activities of these P450s in adult mouse liver. Such persistent induction of P450 gene expression and enzyme activities in adult livers by phenobarbital treatment only occurs within a sensitive age window in early life. With consideration of species differences between mouse and human, these results should stimulate studies to reevaluate the long-term impacts of drug treatment with different doses in neonates and infants, and the resulting interindividual variation in drug metabolism, therapeutic efficacy, and drug-induced toxicity throughout the rest of life.

Interindividual Variability in CYP2D6-Mediated Drug Metabolism (H.J. and X.P.)

CYP2D6 is responsible for the metabolism of approximately 20% of clinically used medications, and plays an important role in drug elimination. Notably, CYP2D6-mediated drug metabolism exhibits large interindividual variability (Sachse et al., 1997; Zanger et al., 2001). Based on CYP2D6 activity levels, an individual can be placed in one of four CYP2D6 phenotype categories: poor metabolizer (PM), intermediate metabolizer (IM), extensive metabolizer (EM), and ultra-rapid metabolizer (UM) (Hou et al., 1991; Dahl et al., 1992; Sachse et al., 1997; Zanger et al., 2001; Bertilsson et al., 2002). Genetic polymorphisms in *CYP2D6* are known to explain part of the interindividual variability. For example,

certain genetic polymorphisms in *CYP2D6*, linked with frame-shift mutations or splicing defects, lead to low or minimal expression of CYP2D6 protein, or the expression of nonfunctional CYP2D6 protein. Carriers of these genetic polymorphisms present with the PM phenotype. To date, over 100 different genetic polymorphisms of *CYP2D6* that are associated with decreased CYP2D6 expression or activity have been identified (http://www.cypalleles.ki.se). Despite accumulating data on how genetic polymorphisms of *CYP2D6* lead to interindividual variability in CYP2D6-mediated metabolism, a large portion of CYP2D6 variability still remains unexplained, especially in non-PM subjects which comprise >90% of population. Gaedigk et al. showed that for individuals carrying equivalently functional alleles of *CYP2D6* (e.g., two copies of wild-type *CYP2D6*), phenotypic CYP2D6 activity levels (as measured by the urinary metabolic ratios of dextrorphan/dextromethorphan) were still highly variable (Gaedigk et al., 2008). Consequently, one cannot reliably predict CYP2D6 activity levels in an individual based solely on CYP2D6 genotype, thus presenting an obstacle to the achievement of personalized medicine.

It was previously shown that the mRNA expression levels of CYP2D6 are well correlated with CYP2D6 activity levels (correlation coefficients range from 0.85 to 0.91) (Carcillo et al., 2003; Temesvari et al., 2012). The correlation coefficients between CYP2D6 mRNA and activity levels were comparable to those observed for CYP3A4, where its expression and activity are governed at the transcriptional level. These results suggest that differential transcriptional regulation of *CYP2D6* may explain part of interindividual variability in CYP2D6-mediated drug metabolism. However, factors involved in the transcriptional regulation of CYP2D6 expression remain poorly defined. Better understanding of the regulation of CYP2D6 expression could potentially lead to identification of factors contributing to interindividual variability in CYP2D6 activity. The following is the summary of our recent work where we identified small heterodimer partner (SHP) as a novel regulator of CYP2D6 expression.

Accumulating clinical evidence indicates that CYP2D6-mediated drug metabolism is increased in pregnant women as compared to the postpartum controls (Hogstedt et al., 1985; Wadelius et al., 1997; Tracy et al., 2005). The underlying mechanisms remained unknown, in part due to a lack of experimental models that can recapitulate CYP2D6 induction during pregnancy. For example, the homolog of CYP2D6

in rodents (e.g., rat CYP2D2) exhibited decreased, rather than increased, expression during pregnancy (Dickmann et al., 2008). CYP2D6-humanized transgenic (Tg-CYP2D6) mice were generated to study CYP2D6-mediated drug metabolism *in vivo*, and its genome harbors the human *CYP2D6* along with its 2.5-kb upstream regulatory region (Corchero et al., 2001). We showed that CYP2D6 expression and activity was enhanced by 2-3-fold at term pregnancy as compared to the pre-pregnancy or postpartum level in Tg-CYP2D6 mice (Koh et al., 2014), establishing these transgenic mice as a potential model to study regulation of CYP2D6 expression in pregnancy.

HNF4α is an abundant transcription factor belonging to the nuclear receptor family NR2A1. HNF4α binds to DNA as a homodimer, and regulates gene expression by recruiting coactivators. In the liver, HNF4α binds to ~40% of the actively transcribed genes in their regulatory regions (Odom et al., 2004) and plays a critical role in regulating expression of genes involved in key hepatic function such as glucose and lipid metabolism (Gonzalez, 2008). While the nature of endogenous ligands for HNF4α remain controversial, studies have shown that HNF4α activity can be modulated by posttranslational modification of HNF4α, or interaction with other transcription factors (Gonzalez, 2008).

HNF4α governs the basal expression of CYP2D6 by binding to the proximal promoter region (Cairns et al., 1996); knock-down of hepatic expression of HNF4α led to a significant decrease in CYP2D6 expression (Corchero et al., 2001). To determine the potential involvement of HNF4α in CYP2D6 induction during pregnancy, the expression levels of HNF4α in livers of Tg-CYP2D6 mice were examined. The results showed that the mRNA or protein expression levels of HNF4α did not differ among different gestational time points (Koh et al., 2014). Interestingly, however, the HNF4α activity level (as reflected in the extent of HNF4α recruitment to the CYP2D6 promoter region; determined by chromatin immunoprecipitation assay) showed a significant increase at term pregnancy as compared to the pre-pregnancy or postpartum level in Tg-CYP2D6 mice (Koh et al., 2014). Based on the findings that HNF4α activity can be modulated by its interaction with other transcription factors (Gonzalez, 2008), microarray experiments were performed to identify transcription factors whose expression was up- or

down-regulated at term pregnancy. This led to identification of SHP, a transcriptional co-repressor, as a gene down-regulated at term pregnancy in livers of Tg-CYP2D6 mice (Koh et al., 2014). Subsequent studies in HepG2 cells and Tg-CYP2D6 mice revealed that SHP represses CYP2D6 expression by decreasing HNF4α transactivation of CYP2D6 promoter. For example, knockdown of SHP expression by using siRNA in Tg-CYP2D6 mice led to enhanced hepatic CYP2D6 expression (Koh et al., 2014). In follow-up studies to identify the upstream regulator(s) of SHP that are responsible for decreased SHP expression at term pregnancy, we found retinoids as a potential contributor. Retinoids are a class of compounds chemically related to vitamin A, which are essential for development and reproduction. All-*trans* retinoic acid (the bioactive form of vitamin A) was previously shown to induce SHP expression in HepG2 cells (Cai et al., 2010). In Tg-CYP2D6 mice, hepatic levels of all-*trans* retinoic acid exhibited a ~2-fold decrease at term pregnancy as compared to the pre-pregnancy levels. Furthermore, administration of all-*trans* retinoic acid to nonpregnant Tg-CYP2D6 mice for 5 days led to decreased CYP2D6 and increased SHP expression (Koh et al., 2014). Importantly, these results illustrate how altered hepatic retinoid levels (e.g., during pregnancy) may modulate CYP2D6 expression.

SHP is a representative target gene of a bile acid sensor, FXR (Parks et al., 1999). When hepatic concentrations of bile acids are high (e.g., in cholestasis), the ligand-activated FXR transactivates the SHP promoter (Goodwin et al., 2000). SHP in turn represses the expression of genes involved in bile acid synthesis and uptake in the liver (e.g., CYP7A1), protecting the liver from the toxicity of excess bile acids (Li and Chiang, 2014). Whether FXR activation and subsequent changes in SHP expression could lead to altered CYP2D6 expression remained unknown. To characterize the effects of FXR activation on CYP2D6 expression, a synthetic agonist of FXR, GW4064 (Maloney et al., 2000), was administered to Tg-CYP2D6 mice for 5 days, and hepatic CYP2D6 expression was examined. The results showed that GW4064 significantly increased SHP expression by ~2-fold, and this was accompanied by ~2-fold decreases in the expression and activity levels of CYP2D6 in the mice (Pan et al., 2015). The decrease in CYP2D6 expression by GW4064 was abrogated in mice without SHP expression (i.e., *Shp(-/-);CYP2D6* mice), indicating an essential role of SHP in GW4064 action on CYP2D6 expression. The effects of FXR

14

activation (and subsequent SHP induction) on CYP2D6 expression were further examined by using an estrogen-induced cholestasis model. Ethinyl estradiol (EE2) was administered to Tg-CYP2D6 mice at a high dose (10 mg/kg) for 5 days, and CYP2D6 expression was examined. Cholestasis triggered by EE2 led to a 2- to 3-fold decrease in CYP2D6 expression and a ~2-fold increase in SHP expression in the mice (Pan and Jeong, 2015). The repressive effects of GW4064 and bile acids on CYP2D6 expression were also observed in primary human hepatocytes (Pan et al., 2015), suggesting that the action of SHP modulators on CYP2D6 expression is conserved between humans and mice. Together, the results indicate that FXR activation by drugs or bile acids represses CYP2D6 expression through upregulating SHP.

These studies have demonstrated that SHP modulators, including bile acids and retinoids, alter CYP2D6 expression (Figure 3). Whether differential hepatic levels of SHP modulators contribute to interindividual variability in CYP2D6 activity remains unknown. Of note, hepatic levels of vitamin A and bile acids exhibit ~300-fold and ~100-fold variability, respectively (Ukleja et al., 2002; Bentayeb et al., 2008; Garcia-Canaveras et al., 2012). The extent of CYP2D6 variability explained by these SHP modulators and their contribution to CYP2D6 variability (relative to that by the genetic variations of CYP2D6 gene) are yet to be defined.

Biomarkers of P450 Activity using Metabolomic Approaches (L.M.S., J.T.-S., and Y.S.L.)

Interindividual variability in enzyme content or activity affects systemic drug exposure and, potentially, drug efficacy and safety. It is generally accepted that CYP3A and CYP2D6 account for the metabolic elimination of approximately 65% of drugs that undergo metabolism (Wienkers and Heath, 2005). In addition, because CYP3A is localized in the liver and small intestine, CYP3A activity contributes extensively to first-pass and systemic metabolism for many drugs. To estimate hepatic and intestinal activity for CYP3A substrates, intravenous and oral doses of probe drugs are required. Phenotyping with a probe drug is a routine, albeit time-consuming process to determine the *in vivo* activity of P450 enzymes. An alternative method of assessing P450 activity is the use of urinary or plasma biomarkers, which may eliminate the risks associated with exogenous drug administration,

15

involves less invasive sampling, and may be more acceptable to patients or study subjects. The application of metabolomics - the comprehensive analysis of small molecules in a biological sample - can be used to explore P450 activity. In general, metabolomic analyses can be classified as targeted or global approaches (Figure 4). For CYP3A and CYP2D6, examples of biomarkers determined by targeted and global metabolomics are discussed briefly and are summarized in Tables 1 and 2.

Biomarkers of CYP3A Activity. Targeted analyses are focused on a small number of metabolites selected *a priori* to study P450 activity. Some endogenous markers have been in use for decades, such as the urinary 6β-hydroxycortisol/cortisol metabolic ratio (reviewed in (Galteau and Shamsa, 2003)), whereas others such as 4β-hydroxycholesterol or 4β,25-dihydroxyvitamin D_3 were identified more recently (Bodin et al., 2001; Wang et al., 2012). Because the formation and subsequent excretion of cortisol follows a diurnal pattern, the 6β-hydroxycortisol/cortisol ratio determined over a long urine collection interval (e.g., 24 hours) is typically reported rather than the concentration of metabolite alone (Ohno et al., 2000; Hu et al., 2009; Luo et al., 2009). Despite numerous studies with urinary 6β-hydroxycortisol, several reports demonstrate a lack of correlation with CYP3A substrates, especially under basal conditions (Chen et al., 2006; Luo et al., 2009; Dutreix et al., 2014). Other metrics of cortisol and its metabolites have been explored, such as the formation clearance of 6β-hydroxycortisol and a summed formation clearance of 6β-hydroxycortisol and 6β-hydroxycortisone (Luo et al., 2009; Peng et al., 2011). As 6β-hydroxycortisol was found to be a substrate of the renal organic anion transporter 3 (OAT3), urinary 6β-hydroxycortisol/cortisol metabolic ratios may be impacted if OAT3 function is altered (Imamura et al., 2014).

Elevated plasma 4β-hydroxycholesterol levels were first identified in patients treated with anti-epileptic drugs that induced CYP3A activity (Bodin et al., 2001). Since the initial study, plasma 4β-hydroxycholesterol and occasionally the 4β-hydroxycholesterol/cholesterol ratio have been studied following rifampin induction (Goodenough et al., 2011; Bjorkhem et al., 2013; Shin et al., 2013) and with inhibitors such as ketoconazole (Goodenough et al., 2011; Shin et al., 2013). Overall, rigorous validation of 4β-hydroxycholesterol as a CYP3A marker has been yet to be performed. However, a

major drawback of 4β-hydroxycholesterol as a biomarker is its very long half-life (~17 days (Diczfalusy et al., 2009)), which may preclude its use in short-term drug-drug interaction studies or when CYP3A activity is changing rapidly.

Given the knowledge of CYP3A-dependent metabolic pathways, Shin et al. studied larger sets of steroids as potential CYP3A biomarkers (Shin et al., 2013). This study employed targeted profiling on an expanded scale to identify steroids that correlated with the systemic clearance of midazolam (Table 1). The investigators predicted midazolam clearance under basal, ketoconazole-inhibited, and rifampin-induced conditions using CYP3A5 genotype, dehydroepiandrosterone (DHEA) concentration, the 7β-hydroxy-DHEA/DHEA ratio, and the 6β-hydroxycortisone/cortisone ratio ($r^2 = 0.70$). Although a substantial portion of the variability was predicted by these factors, the inhibited midazolam clearance was overpredicted for nearly all subjects, and the induced midazolam clearance was less accurately predicted (Shin et al., 2013). Thus, further refinement and validation of these steroid markers are needed.

Compared to the previous approaches, a global metabolomic analysis captures data on thousands of analytes simultaneously using nuclear magnetic resonance (NMR), gas chromatography/mass spectrometry (GC/MS), or liquid chromatography/mass spectrometry (LC/MS) methodologies. Although no global metabolomics studies have been reported looking at basal CYP3A levels, Rahmioglu et al. (Rahmioglu et al., 2011) used global metabolomics to predict the inducibility of CYP3A4 as determined by the urinary quinine parent-to-metabolite ratio following treatment with St. John's wort, and Kim et al. (Kim et al., 2013) studied altered urinary steroids following induction with rifampin. In both studies, the metabolome was extensively altered by PXR induction (Table 1). As PXR can regulate numerous genes (e.g., other P450s, some Phase II enzymes and transporters as reviewed in (Chai et al., 2013)), alterations in levels of some of the listed compounds are likely the result of the induction of genes other than *CYP3A4*. Further *in vitro* and *in vivo* experiments are necessary to verify whether these compounds are truly CYP3A substrates or products, and to determine their utility as biomarkers of CYP3A4 activity.

Biomarkers of CYP2D6 Activity. The number of identified endogenous substrates or products is more limited for CYP2D6 (see Table 2). Much of the identification of substrates and products of

CYP2D6 activity was performed using recombinant enzymes or microsomes. Many of these compounds are thought to be involved in neurological function, including: pinoline, 5-methoxy-*N,N*-dimethyltryptamine (5-MDMT), 5-methoxytryptamine (5-MT), and anandamide (Yu et al., 2003a; Yu et al., 2003b; Snider et al., 2008).

A global metabolomics study was performed in CYP2D6-transgenic mice and control mice to identify differences in the metabolome of brain homogenate and cerebrospinal fluid in these two strains of mice (Cheng et al., 2013). Compounds that were increased in CYP2D6-transgenic mouse brain included: pantothenic acid, *L*-carnitine, and acetyl-*L*-carnitine, and serotonin. Compounds that were increased in CYP2D6-transgenic mouse cerebrospinal fluid included: 2'-deoxycytidine diphosphate (dCDP), N-acetylglucosaminyl-amine, anandamide, L-carnitine, citric acid, and a compound with the formula $C_6H_{12}O_6$. Stearoyl-*L*-carnitine was decreased in the cerebrospinal fluid of these mice (Cheng et al., 2013). To date, no data are available in humans to corroborate these potential CYP2D6 biomarkers identified by *in vitro* methods or in mice.

Recently, we reported the detection and validation of M1, an unknown ion (*m/z* 444.3), that distinguished CYP2D6 poor metabolizers from other phenotypes in urine samples from 189 pediatric subjects (Tay-Sontheimer et al., 2014). As M1 was absent in the urine of CYP2D6 poor metabolizers and present in the urine of all other CYP2D6 phenotypes, our data suggest that M1 may be a product of a reaction catalyzed by CYP2D6. In a healthy adult volunteer study, urinary M1 decreased by 9-fold after potent CYP2D6 inhibition with multiple doses of fluoxetine, and urinary M1 levels were negatively correlated with CYP2D6 activity as determined by the urinary dextromethorphan/dextrorphan ratio (*p* = 0.012). Although the structure of M1 is still unknown, this was the first study to demonstrate the detection of an endogenous biomarker of CYP2D6 activity in humans using a global metabolomics approach.

In summary, the discovery of biomarkers for P450 activity spans targeted assays to a shotgun approach. The key advantages of these endogenous biomarkers are that they can be used in difficult to study populations such as children or pregnant women, in patients when giving a probe drug is not feasible, to perform retrospective studies, or to predict the potential for drug-drug interactions in first-in-

human studies. However, there are important considerations and limitations of the use of endogenous biomarkers. Biomarkers will likely reflect systemic P450 levels but may not reflect intestinal P450 levels (e.g., hepatic, but not intestinal expression of CYP3A). Thus, the prediction of P450-mediated first-pass metabolism by biomarkers may be difficult. Some biomarkers exhibit diurnal variation (e.g., cortisol) and a sufficient urine collection interval, such as 24 hours, may be necessary to obtain a robust estimate of the urinary metabolic ratio (Hu et al., 2009). If the biomarker is to be used to inform dosing decisions, a long urine collection interval may be impractical. In many instances, additional *in vitro* and *in vivo* studies are needed to validate proposed endogenous biomarkers. Unlike probe drugs, the formation of specific metabolites from endogenous compounds may be catalyzed by more than one enzyme (e.g., hydroxy- and epoxy-eicosatrienoic acid ethanolamide metabolites from anandamide (Snider et al., 2008)), which may complicate the interpretation of circulating concentrations or urinary metabolic ratios of endogenous compounds. Furthermore, the extent that these biomarkers reflect P450 activity from neonates to the elderly or in various disease states should be explored. The ultimate goal would be to develop a panel of validated endogenous markers to support the "precision" dosing of narrow therapeutic range drugs or to monitor P450-related changes due to disease, age, genetics or pregnancy.

Authorship Contributions

Wrote or Contributed to the Writing of the Manuscript: all authors

References

Agrawal AK and Shapiro BH (2003) Phenobarbital-imprinted overinduction of adult constituent CYP isoforms. *Pharmacology* **68:**204-215.

Agrawal AK and Shapiro BH (2005) Neonatal phenobarbital imprints overexpression of cytochromes P450 with associated increase in tumorigenesis and reduced life span. *FASEB J* **19:**470-472.

Bentayeb K, Batlle R, Sanchez C, Nerin C, and Domeno C (2008) Determination of bile acids in human serum by on-line restricted access material-ultra high-performance liquid chromatography-mass spectrometry. *J Chromatogr B Analyt Technol Biomed Life Sci* **869:**1-8.

Bertilsson L, Dahl ML, Dalen P, and Al-Shurbaji A (2002) Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs. *Br J Clin Pharmacol* **53:**111-122.

Bjorkhem I, Lovgren-Sandblom A, Leoni V, Meaney S, Brodin L, Salveson L, Winge K, Palhagen S, and Svenningsson P (2013) Oxysterols and Parkinson's disease: evidence that levels of 24S-hydroxycholesterol in cerebrospinal fluid correlates with the duration of the disease. *Neurosci Lett* **555:**102-105.

Bodin K, Bretillon L, Aden Y, Bertilsson L, Broome U, Einarsson C, and Diczfalusy U (2001) Antiepileptic drugs increase plasma levels of 4beta-hydroxycholesterol in humans: evidence for involvement of cytochrome p450 3A4. *J Biol Chem* **276:**38685-38689.

Cai SY, He H, Nguyen T, Mennone A, and Boyer JL (2010) Retinoic acid represses CYP7A1 expression in human hepatocytes and HepG2 cells by FXR/RXR-dependent and independent mechanisms. *J Lipid Res* **51:**2265-2274.

Cairns W, Smith CA, McLaren AW, and Wolf CR (1996) Characterization of the human cytochrome P4502D6 promoter. A potential role for antagonistic interactions between members of the nuclear receptor family. *J Biol Chem* **271:**25269-25276.

Carcillo JA, Adedoyin A, Burckart GJ, Frye RF, Venkataramanan R, Knoll C, Thummel K, Roskos L, Wilson JW, Sereika S, Romkes M, Bebia Z, and Branch RA (2003) Coordinated intrahepatic and extrahepatic regulation of cytochrome p4502D6 in healthy subjects and in patients after liver transplantation. *Clin Pharmacol Ther* **73:**456-467.

Chai X, Zeng S, and Xie W (2013) Nuclear receptors PXR and CAR: implications for drug metabolism regulation, pharmacogenomics and beyond. *Expert Opin Drug Metab Toxicol* **9:**253-266.

Chaudhry AS, Prasad B, Shirasaka Y, Fohner A, Finkelstein D, Fan Y, Wang S, Wu G, Aklillu E, Sim SC, Thummel KE, and Schuetz EG (2015) The CYP2C19 Intron 2 Branch Point SNP is the Ancestral Polymorphism Contributing to the Poor Metabolizer Phenotype in Livers with CYP2C19*35 and CYP2C19*2 Alleles. *Drug Metab Dispos* **43:**1226-1235.

Chaudhry AS, Thirumaran RK, Yasuda K, Yang X, Fan Y, Strom SC, and Schuetz EG (2013) Genetic variation in aldo-keto reductase 1D1 (AKR1D1) affects the expression and activity of multiple cytochrome P450s. *Drug Metab Dispos* **41:**1538-1547.

Chen WD, Fu X, Dong B, Wang YD, Shiah S, Moore DD, and Huang W (2012) Neonatal activation of the nuclear receptor CAR results in epigenetic memory and permanent change of drug metabolism in mouse liver. *Hepatology* **56:**1499-1509.

Chen Y, Ferguson SS, Negishi M, and Goldstein JA (2004) Induction of human CYP2C9 by rifampicin, hyperforin, and phenobarbital is mediated by the pregnane X receptor. *J Pharmacol Exp Ther* **308:**495-501.

Chen YC, Gotzkowsky SK, Nafziger AN, Kulawy RW, Rocci ML, Jr., Bertino JS, Jr., and Kashuba AD (2006) Poor correlation between 6beta-hydroxycortisol:cortisol molar ratios and midazolam clearance as measure of hepatic CYP3A activity. *Br J Clin Pharmacol* **62:**187-195.

Cheng J, Zhen Y, Miksys S, Beyoglu D, Krausz KW, Tyndale RF, Yu A, Idle JR, and Gonzalez FJ (2013) Potential role of CYP2D6 in the central nervous system. *Xenobiotica* **43:**973-984.

Cooper GM, Johnson JA, Langaee TY, Feng H, Stanaway IB, Schwarz UI, Ritchie MD, Stein CM, Roden DM, Smith JD, Veenstra DL, Rettie AE, and Rieder MJ (2008) A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. *Blood* **112:**1022-1027.

Corchero J, Granvil CP, Akiyama TE, Hayhurst GP, Pimprale S, Feigenbaum L, Idle JR, and Gonzalez FJ (2001) The CYP2D6 humanized mouse: effect of the human CYP2D6 transgene and HNF4alpha on the disposition of debrisoquine in the mouse. *Mol Pharmacol* **60:**1260-1267.

Croom EL, Stevens JC, Hines RN, Wallace AD, and Hodgson E (2009) Human hepatic CYP2B6 developmental expression: the impact of age and genotype. *Biochem Pharmacol* **78:**184-190.

Dahl ML, Johansson I, Palmertz MP, Ingelman-Sundberg M, and Sjoqvist F (1992) Analysis of the CYP2D6 gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population. *Clin Pharmacol Ther* **51:**12-17.

de Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, and Goldstein JA (1994) The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. *J Biol Chem* **269:**15419-15422.

Dickmann LJ, Tay S, Senn TD, Zhang H, Visone A, Unadkat JD, Hebert MF, and Isoherranen N (2008) Changes in maternal liver Cyp2c and Cyp2d expression and activity during rat pregnancy. *Biochem Pharmacol* **75:**1677-1687.

Diczfalusy U, Kanebratt KP, Bredberg E, Andersson TB, Bottiger Y, and Bertilsson L (2009) 4beta-hydroxycholesterol as an endogenous marker for CYP3A4/5 activity. Stability and half-life of elimination after induction with rifampicin. *Br J Clin Pharmacol* **67:**38-43.

Dutreix C, Lorenzo S, and Wang Y (2014) Comparison of two endogenous biomarkers of CYP3A4 activity in a drug-drug interaction study between midostaurin and rifampicin. *Eur J Clin Pharmacol* **70:**915-920.

Gaedigk A, Simon SD, Pearce RE, Bradford LD, Kennedy MJ, and Leeder JS (2008) The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. *Clin Pharmacol Ther* **83:**234-242.

Galteau MM and Shamsa F (2003) Urinary 6beta-hydroxycortisol: a validated test for evaluating drug induction or drug inhibition mediated through CYP3A in humans and in animals. *Eur J Clin Pharmacol* **59:**713-733.

Garcia-Canaveras JC, Donato MT, Castell JV, and Lahoz A (2012) Targeted profiling of circulating and hepatic bile acids in human, mouse, and rat using a UPLC-MRM-MS-validated method. *J Lipid Res* **53:**2231-2241.

Gervot L, Rochat B, Gautier JC, Bohnenstengel F, Kroemer H, de Berardinis V, Martin H, Beaune P, and de Waziers I (1999) Human CYP2B6: expression, inducibility and catalytic activities. *Pharmacogenetics* **9:**295-306.

Gonzalez FJ (2008) Regulation of hepatocyte nuclear factor 4 alpha-mediated transcription. *Drug Metab Pharmacokinet* **23:**2-7.

Goodenough AK, Onorato JM, Ouyang Z, Chang S, Rodrigues AD, Kasichayanula S, Huang SP, Turley W, Burrell R, Bifano M, Jemal M, LaCreta F, Tymiak A, and Wang-Iverson D (2011) Quantification of 4-beta-hydroxycholesterol in human plasma using automated sample preparation and LC-ESI-MS/MS analysis. *Chem Res Toxicol* **24:**1575-1585.

Goodwin B, Hodgson E, and Liddle C (1999) The orphan human pregnane X receptor mediates the transcriptional activation of CYP3A4 by rifampicin through a distal enhancer module. *Mol Pharmacol* **56:**1329-1339.

Goodwin B, Jones SA, Price RR, Watson MA, McKee DD, Moore LB, Galardi C, Wilson JG, Lewis MC, Roth ME, Maloney PR, Willson TM, and Kliewer SA (2000) A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. *Mol Cell* **6:**517-526.

Goodwin B, Moore LB, Stoltz CM, McKee DD, and Kliewer SA (2001) Regulation of the human CYP2B6 gene by the nuclear pregnane X receptor. *Mol Pharmacol* **60:**427-431.

Gryn SE, Teft WA, and Kim RB (2014) Profound reduction in the tamoxifen active metabolite endoxifen in a patient on phenytoin for epilepsy compared with a CYP2D6 genotype matched cohort. *Pharmacogenet Genomics* **24:**367-369.

Guengerich FP (2008) Cytochrome p450 and chemical toxicology. *Chem Res Toxicol* **21:**70-83.

Handschin C and Meyer UA (2003) Induction of drug metabolism: the role of nuclear receptors. *Pharmacol Rev* **55:**649-673.

Hart SN, Wang S, Nakamoto K, Wesselman C, Li Y, and Zhong XB (2008) Genetic polymorphisms in cytochrome P450 oxidoreductase influence microsomal P450-catalyzed drug metabolism. *Pharmacogenet Genomics* **18:**11-24.

Hines RN (2007) Ontogeny of human hepatic cytochromes P450. *J Biochem Mol Toxicol* **21:**169-175.

Hogstedt S, Lindberg B, Peng DR, Regardh CG, and Rane A (1985) Pregnancy-induced increase in metoprolol metabolism. *Clin Pharmacol Ther* **37:**688-692.

Hou X, Shi J, and Sun H (2014) Gene polymorphism of cytochrome P450 2C19*2 and clopidogrel resistance reflected by platelet function assays: a meta-analysis. *Eur J Clin Pharmacol* **70:**1041-1047.

Hou ZY, Pickle LW, Meyer PS, and Woosley RL (1991) Salivary analysis for determination of dextromethorphan metabolic phenotype. *Clin Pharmacol Ther* **49:**410-419.

Hu ZY, Zhao YS, Wu D, and Cheng ZN (2009) Endogenous cortisol 6 beta-hydroxylation clearance is not an accurate probe for overall cytochrome P450 3A phenotyping in humans. *Clin Chim Acta* **408:**92-97.

Imamura Y, Tsuruya Y, Damme K, Heer D, Kumagai Y, Maeda K, Murayama N, Okudaira N, Kurihara A, Izumi T, Sugiyama Y, and Kusuhara H (2014) 6beta-Hydroxycortisol is an endogenous probe for evaluation of drug-drug interactions involving a multispecific renal organic anion transporter, OAT3/SLC22A8, in healthy subjects. *Drug Metab Dispos* **42:**685-694.

Kim B, Moon JY, Choi MH, Yang HH, Lee S, Lim KS, Yoon SH, Yu KS, Jang IJ, and Cho JY (2013) Global metabolomics and targeted steroid profiling reveal that rifampin, a strong human PXR activator, alters endogenous urinary steroid markers. *J Proteome Res* **12:**1359-1368.

Koh KH, Pan X, Shen HW, Arnold SL, Yu AM, Gonzalez FJ, Isoherranen N, and Jeong H (2014) Altered expression of small heterodimer partner governs cytochrome P450 (CYP) 2D6 induction during pregnancy in CYP2D6-humanized mice. *J Biol Chem* **289:**3105-3113.

Koukouritaki SB, Manro JR, Marsh SA, Stevens JC, Rettie AE, McCarver DG, and Hines RN (2004) Developmental expression of human hepatic CYP2C9 and CYP2C19. *J Pharmacol Exp Ther* **308:**965-974.

Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, Watkins PB, Daly A, Wrighton SA, Hall SD, Maurel P, Relling M, Brimer C, Yasuda K, Venkataramanan R, Strom S, Thummel K, Boguski MS, and Schuetz E (2001) Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. *Nat Genet* **27:**383-391.

Lacroix D, Sonnier M, Moncion A, Cheron G, and Cresteil T (1997) Expression of CYP3A in the human liver--evidence that the shift between CYP3A7 and CYP3A4 occurs immediately after birth. *Eur J Biochem* **247:**625-634.

Lamba J, Lamba V, Strom S, Venkataramanan R, and Schuetz E (2008) Novel single nucleotide polymorphisms in the promoter and intron 1 of human pregnane X receptor/NR1I2 and their association with CYP3A4 expression. *Drug Metab Dispos* **36:**169-181.

Lamba JK, Lin YS, Schuetz EG, and Thummel KE (2002) Genetic contribution to variable human CYP3A-mediated metabolism. *Adv Drug Deliv Rev* **54:**1271-1294.

Lamba V, Ghodke Y, Guan W, and Tracy TS (2014) microRNA-34a is associated with expression of key hepatic transcription factors and cytochromes P450. *Biochem Biophys Res Commun* **445:**404-411.

Lamba V, Lamba J, Yasuda K, Strom S, Davila J, Hancock ML, Fackenthal JD, Rogan PK, Ring B, Wrighton SA, and Schuetz EG (2003) Hepatic CYP2B6 expression: gender and ethnic differences and relationship to CYP2B6 genotype and CAR (constitutive androstane receptor) expression. *J Pharmacol Exp Ther* **307:**906-922.

23

Lamba V, Panetta JC, Strom S, and Schuetz EG (2010) Genetic predictors of interindividual variability in hepatic CYP3A4 expression. *J Pharmacol Exp Ther* **332:**1088-1099.

Li T and Chiang JY (2014) Bile acid signaling in metabolic disease and drug therapy. *Pharmacol Rev* **66:**948-983.

Li Y, Cui Y, Hart SN, Klaassen CD, and Zhong XB (2009) Dynamic patterns of histone methylation are associated with ontogenic expression of the Cyp3a genes during mouse liver maturation. *Mol Pharmacol* **75:**1171-1179.

Lin JH and Lu AY (1998) Inhibition and induction of cytochrome P450 and the clinical implications. *Clin Pharmacokinet* **35:**361-390.

Lin JH and Lu AY (2001) Interindividual variability in inhibition and induction of cytochrome P450 enzymes. *Annu Rev Pharmacol Toxicol* **41:**535-567.

Luo X, Li XM, Hu ZY, and Cheng ZN (2009) Evaluation of CYP3A activity in humans using three different parameters based on endogenous cortisol metabolism. *Acta Pharmacol Sin* **30:**1323-1329.

Madadi P, Amstutz U, Rieder M, Ito S, Fung V, Hwang S, Turgeon J, Michaud V, Koren G, Carleton BC, and Group CCR (2013) Clinical practice guideline: CYP2D6 genotyping for safe and efficacious codeine therapy. *J Popul Ther Clin Pharmacol* **20:**e369-396.

Maloney PR, Parks DJ, Haffner CD, Fivush AM, Chandra G, Plunket KD, Creech KL, Moore LB, Wilson JG, Lewis MC, Jones SA, and Willson TM (2000) Identification of a chemical tool for the orphan nuclear receptor FXR. *J Med Chem* **43:**2971-2974.

Odom DT, Zizlsperger N, Gordon DB, Bell GW, Rinaldi NJ, Murray HL, Volkert TL, Schreiber J, Rolfe PA, Gifford DK, Fraenkel E, Bell GI, and Young RA (2004) Control of pancreas and liver gene expression by HNF transcription factors. *Science* **303:**1378-1381.

Ohno M, Yamaguchi I, Ito T, Saiki K, Yamamoto I, and Azuma J (2000) Circadian variation of the urinary 6beta-hydroxycortisol to cortisol ratio that would reflect hepatic CYP3A activity. *Eur J Clin Pharmacol* **55:**861-865.

Pan X and Jeong H (2015) Estrogen-Induced Cholestasis Leads to Repressed CYP2D6 Expression in CYP2D6-Humanized Mice. *Mol Pharmacol*.

Pan X, Lee YK, and Jeong H (2015) Farnesoid X Receptor Agonist Represses Cytochrome P450 2D6 Expression by Upregulating Small Heterodimer Partner. *Drug Metab Dispos* **43:**1002-1007.

Parks DJ, Blanchard SG, Bledsoe RK, Chandra G, Consler TG, Kliewer SA, Stimmel JB, Willson TM, Zavacki AM, Moore DD, and Lehmann JM (1999) Bile acids: natural ligands for an orphan nuclear receptor. *Science* **284:**1365-1368.

Peng CC, Templeton I, Thummel KE, Davis C, Kunze KL, and Isoherranen N (2011) Evaluation of 6beta-hydroxycortisol, 6beta-hydroxycortisone, and a combination of the two as endogenous probes for inhibition of CYP3A4 in vivo. *Clin Pharmacol Ther* **89:**888-895.

Peng L, Yoo B, Gunewardena SS, Lu H, Klaassen CD, and Zhong XB (2012) RNA sequencing reveals dynamic changes of mRNA abundance of cytochromes P450 and their alternative transcripts during mouse liver development. *Drug Metab Dispos* **40:**1198-1209.

Preskorn S, Patroneva A, Silman H, Jiang Q, Isler JA, Burczynski ME, Ahmed S, Paul J, and Nichols AI (2009) Comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine in extensive and poor cytochrome P450 2D6 metabolizers. *J Clin Psychopharmacol* **29:**39-43.

Rahmioglu N, Le Gall G, Heaton J, Kay KL, Smith NW, Colquhoun IJ, Ahmadi KR, and Kemsley EK (2011) Prediction of variability in CYP3A4 induction using a combined 1H NMR metabonomics and targeted UPLC-MS approach. *J Proteome Res* **10:**2807-2816.

Rojas L, Neumann I, Herrero MJ, Boso V, Reig J, Poveda JL, Megias J, Bea S, and Alino SF (2014) Effect of CYP3A5*3 on kidney transplant recipients treated with tacrolimus: a systematic review and meta-analysis of observational studies. *Pharmacogenomics J*.

Sachse C, Brockmoller J, Bauer S, and Roots I (1997) Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. *Am J Hum Genet* **60:**284-295.

Saitoh A, Sarles E, Capparelli E, Aweeka F, Kovacs A, Burchett SK, Wiznia A, Nachman S, Fenton T, and Spector SA (2007) CYP2B6 genetic variants are associated with nevirapine pharmacokinetics and clinical response in HIV-1-infected children. *AIDS* **21:**2191-2199.

Shin KH, Choi MH, Lim KS, Yu KS, Jang IJ, and Cho JY (2013) Evaluation of endogenous metabolic markers of hepatic CYP3A activity using metabolic profiling and midazolam clearance. *Clin Pharmacol Ther* **94:**601-609.

Sim SC, Kacevska M, and Ingelman-Sundberg M (2013) Pharmacogenomics of drug-metabolizing enzymes: a recent update on clinical implications and endogenous effects. *Pharmacogenomics J* **13:**1-11.

Snider NT, Sikora MJ, Sridar C, Feuerstein TJ, Rae JM, and Hollenberg PF (2008) The endocannabinoid anandamide is a substrate for the human polymorphic cytochrome P450 2D6. *J Pharmacol Exp Ther* **327:**538-545.

Sridar C, Snider NT, and Hollenberg PF (2011) Anandamide oxidation by wild-type and polymorphically expressed CYP2B6 and CYP2D6. *Drug Metab Dispos* **39:**782-788.

Stevens JC (2006) New perspectives on the impact of cytochrome P450 3A expression for pediatric pharmacology. *Drug Discov Today* **11:**440-445.

Steward DJ, Haining RL, Henne KR, Davis G, Rushmore TH, Trager WF, and Rettie AE (1997) Genetic association between sensitivity to warfarin and expression of CYP2C9*3. *Pharmacogenetics* **7:**361-367.

Sueyoshi T, Kawamoto T, Zelko I, Honkakoski P, and Negishi M (1999) The repressed nuclear receptor CAR responds to phenobarbital in activating the human CYP2B6 gene. *J Biol Chem* **274:**6043-6046.

Takeuchi F, McGinnis R, Bourgeois S, Barnes C, Eriksson N, Soranzo N, Whittaker P, Ranganath V, Kumanduri V, McLaren W, Holm L, Lindh J, Rane A, Wadelius M, and Deloukas P (2009) A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. *PLoS Genet* **5:**e1000433.

Tay-Sontheimer J, Shireman LM, Beyer RP, Senn T, Witten D, Pearce RE, Gaedigk A, Gana Fomban CL, Lutz JD, Isoherranen N, Thummel KE, Fiehn O, Leeder JS, and Lin YS (2014) Detection of an endogenous urinary biomarker associated with CYP2D6 activity using global metabolomics. *Pharmacogenomics* **15:**1947-1962.

Temesvari M, Kobori L, Paulik J, Sarvary E, Belic A, and Monostory K (2012) Estimation of drug-metabolizing capacity by cytochrome P450 genotyping and expression. *J Pharmacol Exp Ther* **341:**294-305.

Tien YC, Liu K, Pope C, Wang P, Ma X, and Zhong XB (2015) Dose of Phenobarbital and Age of Treatment at Early Life are Two Key Factors for the Persistent Induction of Cytochrome P450 Enzymes in Adult Mouse Liver. *Drug Metab Dispos* **43:**1938-1945.

Tracy TS, Venkataramanan R, Glover DD, and Caritis SN (2005) Temporal changes in drug metabolism (CYP1A2, CYP2D6 and CYP3A Activity) during pregnancy. *Am J Obstet Gynecol* **192:**633-639.

Ukleja A, Scolapio JS, McConnell JP, Spivey JR, Dickson RC, Nguyen JH, and O'Brien PC (2002) Nutritional assessment of serum and hepatic vitamin A levels in patients with cirrhosis. *JPEN J Parenter Enteral Nutr* **26:**184-188.

Wadelius M, Darj E, Frenne G, and Rane A (1997) Induction of CYP2D6 in pregnancy. *Clin Pharmacol Ther* **62:**400-407.

Wang Z, Lin YS, Zheng XE, Senn T, Hashizume T, Scian M, Dickmann LJ, Nelson SD, Baillie TA, Hebert MF, Blough D, Davis CL, and Thummel KE (2012) An inducible cytochrome P450 3A4-dependent vitamin D catabolic pathway. *Mol Pharmacol* **81:**498-509.

Westlind A, Lofberg L, Tindberg N, Andersson TB, and Ingelman-Sundberg M (1999) Interindividual differences in hepatic expression of CYP3A4: relationship to genetic polymorphism in the 5'-upstream regulatory region. *Biochem Biophys Res Commun* **259:**201-205.

Wienkers LC and Heath TG (2005) Predicting in vivo drug interactions from in vitro drug discovery data. *Nat Rev Drug Discov* **4:**825-833.

Yang X, Zhang B, Molony C, Chudin E, Hao K, Zhu J, Gaedigk A, Suver C, Zhong H, Leeder JS, Guengerich FP, Strom SC, Schuetz E, Rushmore TH, Ulrich RG, Slatter JG, Schadt EE, Kasarskis A, and Lum PY (2010) Systematic genetic and genomic analysis of cytochrome P450 enzyme activities in human liver. *Genome Res* **20:**1020-1036.

Yu AM, Idle JR, Byrd LG, Krausz KW, Kupfer A, and Gonzalez FJ (2003a) Regeneration of serotonin from 5-methoxytryptamine by polymorphic human CYP2D6. *Pharmacogenetics* **13:**173-181.

Yu AM, Idle JR, Herraiz T, Kupfer A, and Gonzalez FJ (2003b) Screening for endogenous substrates reveals that CYP2D6 is a 5-methoxyindolethylamine O-demethylase. *Pharmacogenetics* **13:**307-319.

Zanger UM, Fischer J, Raimundo S, Stuven T, Evert BO, Schwab M, and Eichelbaum M (2001) Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6. *Pharmacogenetics* **11:**573-585.

26

Footnotes

All authors equally contributed. This work was supported by the National Institute of Health [Grants HD065532, HD058556, GM007750, ES007033, TR000423, TR000421, TR000001, ES019487, and GM087376].

Figure Legends

Figure 1. *CYP2C19*35* and *CYP2C19*2* (both with rs12769205) have relative extended haplotype homozygosity (REHH) scores similar in magnitude to haplotypes associated with malaria resistance. (A) Structure of *CYP2C19*1, *35* and **2* mRNAs and their haplotype frequency in Yorubans (YRI). (B) REHH scores for *CYP2C19*2* and *CYP2C19*35* and for two haplotypes, glucose-6-phosphate dehydrogenase (G6PD) haplotype 8 and TNF receptor superfamily member 5 (TNFSF5) haplotype 4, under positive natural selection for resistance to malaria.

Figure 2. Models of the short- and long-term impact of phenobarbital exposure in early life on drug metabolism in mouse liver. (A) Impact of different doses of phenobarbital in early life. (B) Impact of high doses of phenobarbital at different developmental ages.

Figure 3. Differential transcriptional regulation of CYP2D6 through modulation of SHP expression may explain part of interindividual variability in CYP2D6-mediated drug metabolism.

Figure 4. Workflow for global and targeted metabolomics analyses to determine biomarkers of P450 activity.

Table 1. Examples of Possible Endogenous Biomarkers of CYP3A Activity[1]

11β-hydroxyandrosterone	acetylarginine
11β-hydroxyetiocholanolone	allotetrahydrocortisone
11β-hydroxytestosterone	androstanolone
11-dehydrocorticosterone	androstenedione
11-deoxycortisol	androsterone
11β-hydroxyandrostenedione	androsterone sulfate
16α-hydroxytestosterone	cholesterol
16α-hydroxyandrostenedione	cortisol
16α-hydroxy-DHEA	cortisone
16β-hydroxyestradiol	dehydroepiandrosterone (DHEA)
17α-hydroxypregnenolone	D-glucosaminide
24-hydroxycholesterol	DHEA sulfate
27-hydroxycholesterol	estradiol
2-hydroxyestradiol	estrone
2-hydroxyestrone	etiocholanolone
4β-hydroxycholesterol	glycochenodeoxycholic acid sulfate
4-hydroxyandrostenedione	hydroxytestosterone sulfate
6β-hydroxyandrostenedione	indoxyl sulfate
6β-hydroxycortisol	mannitol-1-phosphate
6β-hydroxycortisone	p-cresol sulfate
7α-hydroxy-DHEA	pregnenolone
7β-hydroxycholesterol	saccharopine
7β-hydroxy-DHEA	scyllo-inositol
25-hydroxyvitamin D_3	testosterone

[1] References: (Bodin et al., 2001; Rahmioglu et al., 2011; Wang et al., 2012; Kim et al., 2013; Shin et al., 2013)

Note: some compounds were identified following PXR induction and have not been verified as being CYP3A substrates or products using standard *in vitro* methods

Table 2. Examples of Possible Endogenous Biomarkers of CYP2D6 Activity[1]

14,15-epoxyeicosatetraenoic acid ethanolamide
20-hydroxyeicosatetraenoic acid ethanolamide (20-HETE ethanolamide)
5-methoxy-*N,N*-dimethyltryptamine (5-MDMT)
5-methoxytryptamine (5-MT)
6-hydroxy-1,2,3,4-tetrahydro-β-carboline
6-methoxy-1,2,3,4-tetrahydro-β-carboline (pinoline)
bufotenine
N-arachidonylethanolamine (anandamide)
serotonin (5-HT)

[1] References: (Yu et al., 2003a; Yu et al., 2003b; Snider et al., 2008; Preskorn et al., 2009; Sridar et al., 2011)

Fig 1

A.

		Haplotype frequency (Yri)
Ex 2	Ex 3	Ex 4	Ex 5	*CYP2C19*1*	78%
	rs12769205		
Ex 2	Ex 2B	Ex 3	Ex 4	Ex 5	*CYP2C19*35*	6%
	rs12769205	rs4244285	
Ex 2	Ex 2B	Ex 3	Ex 4	40 bp	Ex 5	*CYP2C19*2*	17%

B.

	REHH SCORE
*CYP2C19*2*	2.5-5.5
*CYP2C19*35*	10
G6PD	10
TNFSF5	5

Fig 2

Fig 3

Fig 4